anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: 81 mg Aspirin
Eligibility criteria:
Inclusion Criteria:

1. Age 40 to 80 years, inclusive.

2. No previous heart attack or a stroke, or other forms of these diseases.

3. Have at least three of the five characteristics listed below, indicating presence of metabolic syndrome, as defined by NCEP-III:

waist measuring more than 40 inches (for men) or more than 35 inches (for women),
high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women,
triglyceride (TG) levels above 150 mg/dl,
blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic,
fasting blood sugar greater than 110 mg/dl

Exclusion Criteria:

Patients taking greater than 81mg aspirin daily.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin, during the last two weeks.
Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.
Patients who are currently cigarette smokers.
Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.
Patients with any coagulation, bleeding or blood disorders.
Patients who are sensitive or allergic to aspirin.
Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.
Patients with any evidence of cancer or history of significant cardiovascular disease (including heart attack, stroke or drop attacks termed transient ischemic attacks (TIAs), or blockages of the arteries in the legs termed peripheral arterial disease (PAD)), kidney, liver, lung, blood, or brain disorders.
Patients with asthma, rhinitis, or nasal polyps.
Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety.
Patients with Class IV heart failure.
Patients with severe aortic insufficiency, or aortic regurgitation.
Patients with hearing loss or tinnitus.
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: 162 mg Aspirin
Eligibility criteria:
Inclusion Criteria:

1. Age 40 to 80 years, inclusive.

2. No previous heart attack or a stroke, or other forms of these diseases.

3. Have at least three of the five characteristics listed below, indicating presence of metabolic syndrome, as defined by NCEP-III:

waist measuring more than 40 inches (for men) or more than 35 inches (for women),
high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women,
triglyceride (TG) levels above 150 mg/dl,
blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic,
fasting blood sugar greater than 110 mg/dl

Exclusion Criteria:

Patients taking greater than 81mg aspirin daily.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin, during the last two weeks.
Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.
Patients who are currently cigarette smokers.
Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.
Patients with any coagulation, bleeding or blood disorders.
Patients who are sensitive or allergic to aspirin.
Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.
Patients with any evidence of cancer or history of significant cardiovascular disease (including heart attack, stroke or drop attacks termed transient ischemic attacks (TIAs), or blockages of the arteries in the legs termed peripheral arterial disease (PAD)), kidney, liver, lung, blood, or brain disorders.
Patients with asthma, rhinitis, or nasal polyps.
Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety.
Patients with Class IV heart failure.
Patients with severe aortic insufficiency, or aortic regurgitation.
Patients with hearing loss or tinnitus.
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: 325 mg Aspirin
Eligibility criteria:
Inclusion Criteria:

1. Age 40 to 80 years, inclusive.

2. No previous heart attack or a stroke, or other forms of these diseases.

3. Have at least three of the five characteristics listed below, indicating presence of metabolic syndrome, as defined by NCEP-III:

waist measuring more than 40 inches (for men) or more than 35 inches (for women),
high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women,
triglyceride (TG) levels above 150 mg/dl,
blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic,
fasting blood sugar greater than 110 mg/dl

Exclusion Criteria:

Patients taking greater than 81mg aspirin daily.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin, during the last two weeks.
Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.
Patients who are currently cigarette smokers.
Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.
Patients with any coagulation, bleeding or blood disorders.
Patients who are sensitive or allergic to aspirin.
Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.
Patients with any evidence of cancer or history of significant cardiovascular disease (including heart attack, stroke or drop attacks termed transient ischemic attacks (TIAs), or blockages of the arteries in the legs termed peripheral arterial disease (PAD)), kidney, liver, lung, blood, or brain disorders.
Patients with asthma, rhinitis, or nasal polyps.
Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety.
Patients with Class IV heart failure.
Patients with severe aortic insufficiency, or aortic regurgitation.
Patients with hearing loss or tinnitus.
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: 650 mg Aspirin
Eligibility criteria:
Inclusion Criteria:

1. Age 40 to 80 years, inclusive.

2. No previous heart attack or a stroke, or other forms of these diseases.

3. Have at least three of the five characteristics listed below, indicating presence of metabolic syndrome, as defined by NCEP-III:

waist measuring more than 40 inches (for men) or more than 35 inches (for women),
high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women,
triglyceride (TG) levels above 150 mg/dl,
blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic,
fasting blood sugar greater than 110 mg/dl

Exclusion Criteria:

Patients taking greater than 81mg aspirin daily.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin, during the last two weeks.
Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.
Patients who are currently cigarette smokers.
Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.
Patients with any coagulation, bleeding or blood disorders.
Patients who are sensitive or allergic to aspirin.
Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.
Patients with any evidence of cancer or history of significant cardiovascular disease (including heart attack, stroke or drop attacks termed transient ischemic attacks (TIAs), or blockages of the arteries in the legs termed peripheral arterial disease (PAD)), kidney, liver, lung, blood, or brain disorders.
Patients with asthma, rhinitis, or nasal polyps.
Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety.
Patients with Class IV heart failure.
Patients with severe aortic insufficiency, or aortic regurgitation.
Patients with hearing loss or tinnitus.
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 70
Group description: 1300 mg Aspirin
Eligibility criteria:
Inclusion Criteria:

1. Age 40 to 80 years, inclusive.

2. No previous heart attack or a stroke, or other forms of these diseases.

3. Have at least three of the five characteristics listed below, indicating presence of metabolic syndrome, as defined by NCEP-III:

waist measuring more than 40 inches (for men) or more than 35 inches (for women),
high density lipoprotein (HDL) cholesterol levels lower than 40 milligrams per deciliter (mg/dl) in men or 50 mg/dl in women,
triglyceride (TG) levels above 150 mg/dl,
blood pressure greater than 130 millimeters of mercury (mmHg) systolic or 85 mmHg diastolic,
fasting blood sugar greater than 110 mg/dl

Exclusion Criteria:

Patients taking greater than 81mg aspirin daily.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin, during the last two weeks.
Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.
Patients who are currently cigarette smokers.
Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.
Patients with any coagulation, bleeding or blood disorders.
Patients who are sensitive or allergic to aspirin.
Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.
Patients with any evidence of cancer or history of significant cardiovascular disease (including heart attack, stroke or drop attacks termed transient ischemic attacks (TIAs), or blockages of the arteries in the legs termed peripheral arterial disease (PAD)), kidney, liver, lung, blood, or brain disorders.
Patients with asthma, rhinitis, or nasal polyps.
Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety.
Patients with Class IV heart failure.
Patients with severe aortic insufficiency, or aortic regurgitation.
Patients with hearing loss or tinnitus.
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 7
Group description: 162 mg Aspirin
Eligibility criteria:
Inclusion Criteria:

Age 40 to 80 years, inclusive.

Patients with stable coronary disease, with and without diabetes mellitus, defined by:

angiographic evidence of 70% or greater stenosis, or
previous percutaneous coronary intervention (PCI), or
coronary artery bypass graft (CABG), or
history of a MI, or
positive exercise test

Exclusion Criteria:

Patients taking greater than 81mg aspirin daily.
Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.
Patients within 6 months of a coronary intervention, including PCI or CABG.
Patients with a planned coronary intervention.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin.
Patients who are currently cigarette smokers.
Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.
Patients with any coagulation, bleeding or blood disorders.
Patients who are sensitive or allergic to aspirin.
Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.
Patients with any evidence of cancer or kidney, liver, lung, blood, or brain disorders.
Patients with asthma, rhinitis, or nasal polyps.
Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the trial results, be indicative of an underlying disease state, or compromise the safety.
Patients with Class IV heart failure.
Patients with severe aortic insufficiency, or aortic regurgitation.
Patients with hearing loss or tinnitus.
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Intervention: ASPIRIN
Trial phase: Phase 4
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: 1300 mg Aspirin
Eligibility criteria:
Inclusion Criteria:

Age 40 to 80 years, inclusive.

Patients with stable coronary disease, with and without diabetes mellitus, defined by:

angiographic evidence of 70% or greater stenosis, or
previous percutaneous coronary intervention (PCI), or
coronary artery bypass graft (CABG), or
history of a MI, or
positive exercise test

Exclusion Criteria:

Patients taking greater than 81mg aspirin daily.
Patients taking any of the following medications for less than 3 months, or who plan to take them for the first time during the next 3 months: ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers, or statins.
Patients within 6 months of a coronary intervention, including PCI or CABG.
Patients with a planned coronary intervention.
Patients taking anti-platelet drugs such as clopidogrel or non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulant drugs such as warfarin.
Patients who are currently cigarette smokers.
Women patients who are pregnant, planning to become pregnant, nursing a child, or taking hormone replacement therapy.
Patients with any coagulation, bleeding or blood disorders.
Patients who are sensitive or allergic to aspirin.
Patients with documented history of any gastrointestinal disorders, including bleeding ulcers.
Patients with any evidence of cancer or kidney, liver, lung, blood, or brain disorders.
Patients with asthma, rhinitis, or nasal polyps.
Patients with any abnormal laboratory value or physical finding that, in the view of the responsible clinician, may interfere with interpretation of the trial results, be indicative of an underlying disease state, or compromise the safety.
Patients with Class IV heart failure.
Patients with severe aortic insufficiency, or aortic regurgitation.
Patients with hearing loss or tinnitus.
Patients with tremors which cause them not to be able to remain motionless for approximately 30 seconds.
Intervention: Sapropterin Dihydrochloride
Trial phase: Phase 3
SMILES: CC(O)C(O)C1CNc2nc(N)[nH]c(=O)c2N1.Cl.Cl
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 33
Group description: Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
Eligibility criteria:
Inclusion Criteria:

Clinical diagnosis of PKU with hyperphenylalaninemia (HPA) documented by at least one blood Phe measurement >/=360 umol/L (6 mg/dL)
Under dietary control with a Phe-restricted diet as evidenced by:· Estimated daily Phe tolerance </=1000 mg/day
At least 6 months of blood Phe control (mean level of </=480 μmol/L) prior to enrolling in the study
Aged 4 to 12 years inclusive at screening
A blood Phe level </=480 μmol/L at screening
Female subjects of childbearing potential (as determined by the principal investigator) must have a negative blood or urine pregnancy test at entry (prior to the first dose). Note: All female subjects of childbearing potential and sexually mature male subjects must be advised to use a medically accepted method of contraception throughout the study. Female subjects of childbearing potential must be willing to undergo periodic pregnancy tests during the course of the study
Willing and able to comply with all study procedures
Willing to provide written assent (if applicable) and written informed consent by a parent or legal guardian after the nature of the study has been explained and prior to any research-related procedures

Exclusion Criteria:

Any condition that, in the view of the PI, renders the subject at high risk from treatment compliance and/or completing the study
Prior history of organ transplantation
Perceived to be unreliable or unavailable for study participation or have parents or legal guardians who are perceived to be unreliable or unavailable
Use of any investigational agent within 30 days prior to screening, or requirement for any investigational agent or vaccine prior to completion of all scheduled study assessments
ALT > 2 times the upper limit of normal (i.e., Grade 1 or higher based on World Health Organization Toxicity Criteria) at screening
Concurrent disease or condition that would interfere with study participation or safety (e.g., seizure disorder, oral steroid-dependent asthma or other condition requiring oral or parenteral corticosteroid administration, or insulin-dependent diabetes)
Intervention: Caffeine
Trial phase: Phase 2
ATC code: D11AX26 | N06BC01 | R03DA20 | V04CG30
SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 74
Group description: Caffeine benzoate
Eligibility criteria:
Inclusion Criteria:

Children between 2.5-18 years old
Diagnosed with obstructive sleep apnea
Undergoing elective tonsillectomy and adenoidectomy

Exclusion Criteria:

Age below 2.5 or above 18 years
Intervention: FLUTICASONE PROPIONATE
Trial phase: Phase 2
ATC code: D07AC17 | R01AD08 | R01AD58 | R03BA05
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Aerosolized swallowed fluticasone 880 mcg bid for 6 weeks
Eligibility criteria:
Inclusion Criteria:

> 20 eosinophils / hpf on biopsies from mid esophagus (hpf = high-powered field)
Abnormal dysphagia questionnaire (question 1a "yes", question 1c > "moderate" and question 2 > "less than once a week") on Mayo Dysphagia Questionnaire.

Exclusion Criteria:

Clinical evidence of infectious process potentially contributing to dysphagia (e.g., candidiasis, cytomegalovirus, herpes)
Systemic or topical steroid therapy for any reason over the past 3 months
Previous steroid treatment for Eosinophilic Esophagitis
Intolerance to steroid therapy in the past
Other cause of dysphagia identified at endoscopy (e.g., reflux esophagitis, stricture, web, ring, achalasia, esophageal neoplasm)
Dilatation of esophagus at time of index endoscopy